efficacy and adverse events in 2 different SLIT tablets for house dust mite allergy
Not Applicable
- Conditions
- house dust mite - nasal allergy
- Registration Number
- JPRN-UMIN000021195
- Lead Sponsor
- Otorhinolaryngology, Saitama Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
pregnant at the start of treatment patients who suffered from malignancy and/or connective tissue disase patinents who have uncontrolled athma patients who have severe heart diseases or stroke patients who are prescribed beta-antatonisit patnets who are prescribed oral steroid (5mg>=)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method nasal symptom score, medication score, symptom-medication score, QOL, adverse events
- Secondary Outcome Measures
Name Time Method process of HDM sepecific IgE, IgG4 during and after SLIT novel allergen sensitaization, asthma prevalence rate after SLIT